No Data
No Data
NewAmsterdam Pharma Company N.V.'s (NASDAQ:NAMS) Intrinsic Value Is Potentially 72% Above Its Share Price
Analysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)
Newamsterdam Pharma Co Insider Sold Shares Worth $707,400, According to a Recent SEC Filing
NewAmsterdam Pharma Management to Meet With Piper Sandler
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
While Institutions Own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), Private Equity Firms Are Its Largest Shareholders With 47% Ownership